Vol 8, Supplement 4 (December 31, 2019): Translational Lung Cancer Research

The characteristics and prognostic role of thymic epithelial tumors with paraneoplastic autoimmune syndromes

Kyoji Hirai, Jitsuo Usuda

PDF Pages: S321-S322 Full Text (679) Open Access

Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?

Pascale Tomasini, Laurent Greillier

PDF Pages: S323-S326 Full Text (1091) Open Access

Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?

Laura Le, Ritchell van Dams, Percy Lee

PDF Pages: S327-S330 Full Text (1568) Open Access

Myeloid-derived suppressor cell-dependent inhibition of B cell responses in non-small cell lung cancer

Rui Li, Steven M. Dubinett

PDF Pages: S331-S333 Full Text (1061) Open Access

Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints

Antonio Passaro, Filippo de Marinis

PDF Pages: S334-S338 Full Text (1197) Open Access

Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?

Maria A. Velez, Timothy F. Burns

PDF Pages: S339-S342 Full Text (2216) Open Access

Surveillance imaging for non-small cell lung cancer: mounting evidence that less is more

Angel Moran, Megan E. Daly

PDF Pages: S343-S346 Full Text (868) Open Access

Impact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors

Jyoti Malhotra, Salma K. Jabbour, Sharon Pine

PDF Pages: S347-S350 Full Text (1007) Open Access

Can liquid biopsy-guided EGFR-targeted therapy be a surrogate for the tissue-based standard approach?

In-Jae Oh

PDF Pages: S351-S354 Full Text (727) Open Access

Improving outcomes for brain metastases in EGFR mutated NSCLC

Jennifer W. Carlisle, Suresh S. Ramalingam

PDF Pages: S355-S359 Full Text (1484) Open Access

Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock

Caterina Fumagalli, Elena Guerini-Rocco, Massimo Barberis

PDF Pages: S360-S363 Full Text (907) Open Access

Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer

Maria Jove, Noelia Vilariño, Ernest Nadal

PDF Pages: S364-S368 Full Text (2271) Open Access

Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer

Satomi Tanaka, Junji Uchino

PDF Pages: S369-S372 Full Text (1255) Open Access

Opioid use and abuse following video-assisted thoracic surgery (VATS) or thoracotomy lung cancer surgery

Tamar B. Nobel, Prasad S. Adusumilli, Daniela Molena

PDF Pages: S373-S377 Full Text (1076) Open Access

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option

Biagio Ricciuti, Giuseppe Lamberti, Fausto Roila, Giulio Metro

PDF Pages: S378-S382 Full Text (1060) Open Access

Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?

Alice Mogenet, Pascale Tomasini, Laurent Greillier, Fabrice Barlesi

PDF Pages: S383-S386 Full Text (2396) Open Access

Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach

Jacek Jassem

PDF Pages: S387-S390 Full Text (1120) Open Access

Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer

Katsuhiro Masago, Yoshitsugu Horio, Shiro Fujita, Yasushi Yatabe

PDF Pages: S391-S394 Full Text (1317) Open Access

For a better adjuvant strategy for resected lung cancer—lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104)

Kenichi Suda

PDF Pages: S395-S399 Full Text (1230) Open Access

The importance of the false-negative rate to validate a staging protocol for non-small cell lung cancer

Carme Obiols, Sergi Call, Ramon Rami-Porta

PDF Pages: S400-S402 Full Text (689) Open Access

KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit

Amy Lauren Cummings, Edward B. Garon

PDF Pages: S403-S406 Full Text (1495) Open Access

Local consolidative therapy for oligometastatic patients with stage IV non-small cell lung cancer may improve survival, but unanswered questions remain

Jose M. Pacheco, Drew Moghanaki

PDF Pages: S407-S411 Full Text (1183) Open Access

The natural course of incidentally detected, small, subsolid lung nodules—is follow-up needed beyond current guideline recommendations?

Benedikt H. Heidinger, Mario Silva, Constance de Margerie-Mellon, Paul A. VanderLaan, Alexander A. Bankier

PDF Pages: S412-S417 Full Text (7358) Open Access

Optimal management of pulmonary ground-glass opacity nodules

Yeon Wook Kim, Choon-Taek Lee

PDF Pages: S418-S424 Full Text (7834) Open Access

Ground glass nodules with 5 years’ stability can grow after 10-year follow-up: do genetic features determine the fate?

Yoshihisa Kobayashi, Tetsuya Mitsudomi

PDF Pages: S425-S427 Full Text (60768) Open Access

Surveillance of ground glass nodules—when is enough, enough?

Frank C. Detterbeck

PDF Pages: S428-S429 Full Text (924) Open Access

Molecular studies of lung neuroendocrine neoplasms uncover new concepts and entities

Lynnette Fernandez-Cuesta, Matthieu Foll

PDF Pages: S430-S434 Full Text (1602) Open Access

Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases

Laura Bonanno, Alberto Pavan, Stefano Indraccolo

PDF Pages: S435-S438 Full Text (687) Open Access

Spread through air spaces in lung neuroendocrine tumor

Yuka Kozuma, Gouji Toyokawa, Yuichi Yamada, Fumihiro Shoji, Koji Yamazaki, Yoshinao Oda, Sadanori Takeo

PDF Pages: S439-S442 Full Text (963) Open Access

Lung neuroendocrine tumors: a new addition to the evolving list of spread through air spaces

Hironori Uruga, Mari Mino-Kenudson

PDF Pages: S443-S446 Full Text (879) Open Access

Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what’s known and what’s next

Tao Jiang, Caicun Zhou, Jie Hu, Yuanlin Song

PDF Pages: S447-S450 Full Text (1337) Open Access

ERAS in VATS—do we really need to follow the trend?

Hussein Elkhayat, Diego Gonzalez-Rivas

PDF Pages: S451-S453 Full Text (1035) Open Access

Optimizing selection of candidates for lung cancer screening: role of comorbidity, frailty and life expectancy

Shailesh Advani, Dejana Braithwaite

PDF Pages: S454-S459 Full Text (1175) Open Access

Text-mining in cancer research may help identify effective treatments

Yi-Wen Hsiao, Tzu-Pin Lu

PDF Pages: S460-S463 Full Text (1014) Open Access

CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?

Jose Carlos Benitez, Jordi Remon, Benjamin Besse

PDF Pages: S464-S467 Full Text (1479) Open Access

Importance of semaphorins in cancer immunity

Li-Han Chen, Eric Y. Cuang

PDF Pages: S468-S470 Full Text (926) Open Access

Vol 8, Supplement 4 (December 31, 2019): Translational Lung Cancer Research

Editorial Commentary

Letter to the Editor

News